(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

Verve Therapeutics stock jumped after a report said pharmaceutical giant Eli Lilly is in advanced talks to buy the ...

In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...

Eli Lilly is in talks to buy gene editing partner Verve Therapeutics for up to $1.3 billion, according to a report in ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

At 5:33 a.m. ET, Dow E-minis were down 269 points, or 0.63%, S&P 500 E-minis were down 37.25 points, or 0.62%. Nasdaq 100 ...

SunRun shares are plunging 25%, SolarEdge Technologies stock is diving 20%, and Enphase Energy is sliding 15% after Senate Republicans proposed [an end to win ...

Verve Therapeutics is at the forefront of a new ... Partnership with Eli Lilly: Verve’s collaboration with Eli Lilly (NYSE:LLY) is a significant asset for the company. Analysts anticipate ...

Verve Therapeutics continues to engage with investors, offering insights into their clinical trials and future plans. The company is poised for several key milestones, including potential ...

Verve Therapeutics, Inc., a clinical-stage company ... Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad ...